{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T20:10:03Z","timestamp":1756325403709,"version":"3.44.0"},"reference-count":5,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,5,15]]},"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>The combination of glecaprevir and pibrentasvir was recently approved for chronic hepatitis C virus (HCV) infection with recommended treatment duration of 8\u201312 weeks depending on previous treatments, viral genotype and cirrhosis status. Although liver injury was reported with other protease inhibitors in the presence of cirrhosis or hepatitis B virus (HBV) co-infection, glecaprevir\/pibrentasvir treatment is not known to cause liver injury. We report a patient with chronic HCV infection who despite the absence of cirrhosis and HBV co-infection developed acute liver injury that completely resolved after glecaprevir\/pibrentasvir withdrawal. Interestingly, sustained HCV virologic response was achieved after only 3\u2009weeks of glecaprevir\/pibrentasvir treatment.<\/jats:p>","DOI":"10.1136\/bcr-2018-226622","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T06:05:41Z","timestamp":1558764341000},"page":"e226622","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Glecaprevir\/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection"],"prefix":"10.1136","volume":"12","author":[{"given":"Muhammad Baraa","family":"Hammami","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Florida Atlantic University, Boca Raton, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Aboushaar","sequence":"additional","affiliation":[{"name":"Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyad","family":"Alsabbagh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Saint Louis University, Saint Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"2025082712275947000_12.5.e226622.1","unstructured":"Fda.gov. FDA approves Mavyret for Hepatitis C. 2017 https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm570038.htm (accessed 20 Feb 2018)."},{"key":"2025082712275947000_12.5.e226622.2","unstructured":"Livertox.nih. HCV Protease Inhibitors. 2018. Updated January 01 https:\/\/livertox.nih.gov\/HCVProteaseInhibitors.htm (accessed 20 Feb 2018)."},{"key":"2025082712275947000_12.5.e226622.3","unstructured":"Hcvguidelines.org. Recommendations for Testing, Managing, and Treating Hepatitis C | HCV Guidance. 2017. Updated September 21 https:\/\/www.hcvguidelines.org\/ (accessed 20 Feb 2018)."},{"key":"2025082712275947000_12.5.e226622.4","doi-asserted-by":"crossref","unstructured":"Dufour JF , Zuckerman E , Zadeikis N , et al . Safety of Glecaprevir\/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection: An Integrated Analysis. Amsterdam, The Netherlands: Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL), 2017.","DOI":"10.1016\/S0016-5085(17)33670-3"},{"key":"2025082712275947000_12.5.e226622.5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/acs.biochem.7b01160","article-title":"Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C Infection","volume":"57","author":"Matthew","year":"2018","journal-title":"Biochemistry"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:28:10Z","timestamp":1756322890000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":5,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,24]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/bcr-2018-226622"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226622","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}